Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …

Selenium (Se)-containing compounds have emerged as potential therapeutic agents for the
treatment of a range of diseases. Through tremendous effort, considerable knowledge has …

The main protease (M pro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) is a key enzyme, which extensively digests CoV replicase polyproteins essential for viral …

SARS-CoV-2 is the causative agent of the COVID-19 pandemic. The approval of vaccines
and small-molecule antivirals is vital in combating the pandemic. The viral polymerase …

The viral main protease is one of the most attractive targets among all key enzymes involved
in the SARS-CoV-2 life cycle. Covalent inhibition of the cysteine145 of SARS-CoV-2 MPRO …

Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …

The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

The emergence of a new coronavirus, severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), presents an urgent public health crisis. Without available targeted therapies …

The emergence of severe acute respiratory syndrome (SARS-CoV-2) in 2019 marked the
third occurrence of a highly pathogenic coronavirus in the human population since 2003. As …